Ologene Medtech has officially confirmed, based on the latest draft proposal of the 2029 IPAY Medicare Drug Price Negotiation Program, that the company expects its royalty income will not be significantly affected before 2035, with the anticipated impact being zero or minimal.

Ologene Medtech has officially confirmed, based on the latest draft proposal of the 2029 IPAY Medicare Drug Price Negotiation Program, that the company expects its royalty income will not be significantly affected before 2035, with the anticipated impact being zero or minimal.

老虎证券2026/06/15 10:09

Show original

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

This evaluation provides investors with clear guidance regarding the company's long-term revenue prospects, alleviating market concerns about potential policy changes impacting its core revenue streams.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Ologene Medtech has officially confirmed, based on the latest draft proposal of the 2029 IPAY Medicare Drug Price Negotiation Program, that the company expects its royalty income will not be significantly affected before 2035, with the anticipated impact being zero or minimal.

You may also like

Crypto prices